Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-01

Study Completion Date

2020-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Intralesional Injection of Platelet Rich Plasma in the Treatment of Patients With Erosive Oral Lichen Planus

NCT03293368

Erosive Oral Lichen Planus

COMPLETED PHASE2

Different Treatment Modalities for Oral Lichen Plan

NCT06681090

Oral Lichen Planus

COMPLETED PHASE1

Evaluation of Diode Laser and Topical Steroid Therapy in the Treatment of Erosive Oral Lichen Planus

NCT05951361

Erosive Oral Lichen Planus

COMPLETED NA

Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus With Immunohistochemical Analysis

NCT05882864

Oral Lichen Planus

UNKNOWN PHASE4

Glutamine With Topical Corticosteroids for Lichen Planus Treatment

NCT04442633

Lichen Penis Planus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity as well as the objective disease severity scores will be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Lichen Planus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

double equal arms

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

participant, investigator as well as outcome assessor are blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Orochem (Test)

fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.

Group Type EXPERIMENTAL

Matrix Metalloproteinase Inhibitors (Orochem)

Intervention Type DRUG

topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus

Conventional (Control)

fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.

Group Type ACTIVE_COMPARATOR

Kenacort A,

Intervention Type DRUG

topical application of both drugs 3 times daily for 3 weeks as an active control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Matrix Metalloproteinase Inhibitors (Orochem)

topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus

Intervention Type DRUG

Kenacort A,

topical application of both drugs 3 times daily for 3 weeks as an active control

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

miconaz gel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed with erosive OLP confirmed with a biopsy.
* patients should have symptomatic lesions

Exclusion Criteria

* Patients who were under anticoagulant medications, suffering from any systemic diseases or having any physical or mental abnormality, pregnant and lactating women, smokers.

Minimum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No